newsfilter
← Latest News
GlobeNewswire·

BioAge Labs Reports Second Quarter 2026 Financial Results and Provides Business Updates

BIOA
  • BioAge Labs dosed the first participant in QUELL-CV, a Phase 2 dose-ranging trial of BGE-102 for obesity & elevated cardiovascular risk, with topline data expected in the second half of 2026.
  • The QUELL-CV trial is a randomized, double-blind, placebo-controlled study of approximately 160 adults evaluating three once-daily oral doses (30 mg, 60 mg, 90 mg) against placebo over 12 weeks.
  • QUELL-CV's primary endpoint is the percent change from baseline in hsCRP, while the trial aims to characterize dose-response relationships to support future development.
  • BioAge plans to initiate the QUELL-DME Phase 1b/2a proof-of-concept trial for diabetic macular edema in mid-2026, anticipating results in mid-2027 to support development in inflammation-driven retinal diseases.
  • Phase 1 data demonstrated BGE-102 achieved up to 98% suppression of IL-1β & median hsCRP reductions of 86%, with no serious adverse events or treatment-emergent discontinuations reported.
  • The company hosted an R&D Day in May 2026 to present Phase 1 data on BGE-102 & the therapeutic rationale for NLRP3 inhibition across multiple disease areas.
  • BioAge is advancing its APJ agonist program, including a novel antibody under option agreement with JiKang Therapeutics, with an intent to file its first IND by year-end 2026.
  • Strategic collaborations with Novartis on aging biology targets & with Lilly ExploR&D on metabolic aging antibodies continue to progress.
  • Second quarter 2026 collaboration revenue was $2.4 million, while research & development expenses rose to $24.4 million due to direct costs for BGE-102 programs & stock-based compensation.
  • General & administrative expenses were $7.4 million for the quarter, primarily driven by higher personnel-related expenses offset by decreased legal fees.
  • The company reported a net loss of $26.1 million ($0.58 per share) for the quarter ended June 30, 2026, compared to a net loss of $21.6 million in the prior year period.
  • As of June 30, 2026, BioAge held approximately $381.3 million in cash, cash equivalents, & marketable securities, sufficient to fund operations through 2029.